16D0 Brody, Jonathan - Thomas Jefferson University - Thomas Jefferson University

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Room 623
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells
  2. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy
  3. Delivery of Therapeutics Targeting the mRNA Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
  4. The landscape of pancreatic cancer therapeutic resistance mechanisms
  5. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  6. Cancer of the pancreas
  7. Novel targets in pancreatic cancer research
  8. Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: Native ribonucleoprotein immunoprecipitation (RIP) assays
  9. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
  10. MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer
  11. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells
  12. Upgrading gemcitabine with recycled kinase inhibitors
  13. Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types
  14. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells
  15. Commentary : Fusing transcriptomics to progressive prostate cancer
  16. PARP inhibitors for chemoprevention - Letter
  17. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
  18. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial
  19. Structural implications for selective targeting of PARPs
  20. Targeting cell cycle and hormone receptor pathways in cancer